The Europe continuous glucose monitoring systems market value is growing at a significant pace owing to the rise in diabetic population and increase in adoption rate of CGM devices. Key players focus on new product development to meet the specific requirements of the researchers. For instance, in May 2016, Senseonics Holdings Inc. received CE mark approval for Eversense CGM system that includes implantable glucose sensor, a wearable transmitter, and a mobile app.
The Europe continuous glucose monitoring systems market is expected to reach $792 million by 2022, supported by a CAGR of 44.9% during the forecast period. The Europe continuous glucose monitoring systems market is the second largest market of the global continuous glucose monitoring systems market. Continuous glucose monitoring systems (CGMS) are used to constantly monitor glucose levels in diabetic patients, thereby helping in reducing the risk of developing long-term diabetic complications by stabilizing the elevated glucose levels.
The Europe continuous glucose monitoring systems market is expected to witness significant growth from 2016 to 2022, owing to numerous advantages of CGMS such as minimal invasiveness and real-time blood glucose monitoring. In addition, increase in per capita healthcare expenditure, increase in incidence of diabetes in Europe, and growth in purchasing power due to high disposable income of individuals are expected to fuel the EU CGMS market growth.
The Europe continuous glucose monitoring systems market is expected to witness significant growth from 2016 to 2022, owing to numerous advantages of CGMS such as minimal invasiveness and real-time blood glucose monitoring. In addition, increase in per capita healthcare expenditure, increase in incidence of diabetes in Europe, and growth in purchasing power due to high disposable income of individuals are expected to fuel the EU CGMS market growth.
Get Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/862
Key players profiled in this report include
• Abbott Laboratories
• DexCom Inc.
• Echo Therapeutics Inc.
• Insulet Corporation
• Johnson & Johnson
• Medtronic plc
• Senseonics Holding Inc.
• F. Hoffmann-La Roche Ltd.
Other players operating in this market include
• AgaMatrix, Inc.
• GlySure
• OrSense
• Ypsomed
Furthermore, the ability of CGMS to provide detailed analysis of blood glucose levels and higher precision as compared to traditional blood glucose monitoring supplements this growth. However, high costs associated with CGMS, lack of adequate reimbursement policies, and stringent government regulations restrict the global continuous glucose monitoring systems market as well as Europe continuous glucose monitoring systems market.
Agreement and partnership are other key strategies adopted by the key players. These strategies between different companies, healthcare facilities, and academic institutions can positively impact the market growth. For instance, in May 2016, Senseonics signed a distributive agreement with Roche to market and sell Eversense CGM system in Germany, the Netherlands, and Italy.
Make Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/862
KEY BENEFITS FOR STAKEHOLDERS
• This Europe continuous glucose monitoring systems market report provides an extensive analysis of the current EU CGMS market trends and future estimations.
• The market scenario is comprehensively analyzed with respect to the components, demographics, and end users.
• Market estimations are based on high-end analysis of the key developments from 2014 to 2022.
• Recent developments and key manufacturers are listed to understand the competitive market scenario.
• In-depth analysis based on geography provides an understanding of the regional market, which assists in strategic business planning.
Access the latest trends and insights: https://www.alliedmarketresearch.com/europe-continuous-glucose-monitoring-systems-market
Key players profiled in this report include
• Abbott Laboratories
• DexCom Inc.
• Echo Therapeutics Inc.
• Insulet Corporation
• Johnson & Johnson
• Medtronic plc
• Senseonics Holding Inc.
• F. Hoffmann-La Roche Ltd.
Other players operating in this market include
• AgaMatrix, Inc.
• GlySure
• OrSense
• Ypsomed
Furthermore, the ability of CGMS to provide detailed analysis of blood glucose levels and higher precision as compared to traditional blood glucose monitoring supplements this growth. However, high costs associated with CGMS, lack of adequate reimbursement policies, and stringent government regulations restrict the global continuous glucose monitoring systems market as well as Europe continuous glucose monitoring systems market.
Agreement and partnership are other key strategies adopted by the key players. These strategies between different companies, healthcare facilities, and academic institutions can positively impact the market growth. For instance, in May 2016, Senseonics signed a distributive agreement with Roche to market and sell Eversense CGM system in Germany, the Netherlands, and Italy.
Make Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/862
KEY BENEFITS FOR STAKEHOLDERS
• This Europe continuous glucose monitoring systems market report provides an extensive analysis of the current EU CGMS market trends and future estimations.
• The market scenario is comprehensively analyzed with respect to the components, demographics, and end users.
• Market estimations are based on high-end analysis of the key developments from 2014 to 2022.
• Recent developments and key manufacturers are listed to understand the competitive market scenario.
• In-depth analysis based on geography provides an understanding of the regional market, which assists in strategic business planning.
Access the latest trends and insights: https://www.alliedmarketresearch.com/europe-continuous-glucose-monitoring-systems-market
No comments:
Post a Comment